Press releases

The aim of Annual European Congress of Rheumatology EULAR 2022 is to provide a forum of the highest standard for scientific (both clinical and basic)...
2022-03-25 06:00 Lipum AB – Year-end report 2021 Regulatory
CEO Einar Pontén comments: “The last quarter of the year was largely characterized by the fact that we completed activities that constitute...
Lipum AB and QPS The Netherlands BV are pleased to announce a collaboration on the first-in-human study of SOL-116 with the aim of becoming a new treatment...
Lipum's biological drug candidate SOL-116 has successfully been manufactured under the regulations that apply to Good Manufacturing Practice (GMP). The...
2022-02-02 13:00 Lipum recruits scientist
Lipum's development work is in an intensive phase and an initial clinical phase 1 study is being prepared. Preclinical studies have previously shown promising...
2021-12-22 13:00 Lipum AB - report from extra general meeting Regulatory
Decision on the introduction of incentive programs for employees and consultants The meeting resolved that the program shall consist of a maximum of 72,500...
CEO Einar Pontén comments: “We are progressing according to plan and both toxicology- and safety studies, according to GLP, as well as GMP...
Flerie Invest AB is a reputable investment company with active ownership in biotechnology and pharmaceuticals. The company is controlled by Thomas Eldered...
With an ongoing program including toxicology- and safety studies, as well as GMP manufacturing of the drug candidate SOL-116, Lipum is in a late pre-clinical...
The Scientific Advisory Board of Lipum constitute an invaluable resource of experience from academic research to clinical practice within the field chronic...

Investor relations